search
Back to results

Nutrition for Brain and Body Health (BB-Health) Feasibility Trial (BB-Health)

Primary Purpose

Cognition, Obesity

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Multicomponent nutrition supplement (MCNS)
Behavioral weight loss program
Sponsored by
Tufts University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cognition

Eligibility Criteria

55 Years - 85 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Major inclusion criteria:

  1. Adult women and men aged 55-85 years.
  2. BMI of 27.0-39.9 kg/m2 at screening (higher BMIs not included at this time to facilitate program adherence);
  3. Scores of 34 or greater on the Modified Telephone Interview for Cognitive Status (TICS-M) at screening (85). The purpose of this screen is to ensure that participants can give consent and adhere to the study requirements, including the outcomes testing.
  4. Willing to be randomized and participate in all study components, including consuming the foods and supplements, participating in the WL intervention or control meetings, being available for outcome assessments, using the provided home Wi-Fi scale and activity monitor daily, and completing questionnaires, as well as providing the login information for scales and activity monitor so investigators can download the data.
  5. Satisfactory screening review of health history questionnaire by nursing staff for relevant factors including no evidence of exclusions listed below. This will include verbal confirmation of completing a course of vaccination against COVID-19 (two doses plus one booster prior to screening visit). The reason for this study component is that live group meetings are planned with other participants, and this will reduce participant risk.
  6. Has access to computer or smartphone with Wi-Fi and possesses a freezer at home with space for supplement storage.
  7. Rates representative food with characteristics of the MCNS and control foods at least 4 on a 5-point scale of liking at screening, and reports that they are willing to consume the food daily.
  8. Average energy intake in 3 24-h dietary recalls is within physiological (i.e., plausible) range.

Major exclusion criteria:

  1. >25% percentile in most recent data for US adult population intake for reported DHA/EPA in screening questionnaire for rich food sources, which is equivalent to 2 or more servings of fatty fish/month (86, 87).
  2. Regularly taking a multivitamin, cacao/cocoa supplement, choline supplement, DHA/EPA supplement, or any supplement advertised for brain health or cognitive function (>1/week). Washout period of 2 months accepted.
  3. Does not like, or alternatively reports eating >1 serving per week of >60% chocolate or cocoa.
  4. Severe cardiovascular disease including stroke, heart failure, coronary bypass and valve replacement, coronary bypass or any surgical procedures or signs and symptoms of current severe cardiovascular disease.
  5. History of neurological brain disease, including stroke, seizure disorders, traumatic brain injury (moderate to severe); including prior diagnosis of a neurodegenerative disease including AD and Parkinson's disease, frontotemporal dementia. Moderate traumatic brain injury is defined by an injury with loss of consciousness.
  6. Major psychiatric disorder history (schizophrenia, bipolar affective disorder, intractable depression).
  7. Inadequately controlled hypertension at the discretion of study MD or RN
  8. Diabetes Type 1 & Type 2 or use of any pharmacological treatment for diabetes or HbA1c >6.5 at screening.
  9. Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol. This includes the lost of smell or taste.
  10. History of stomach or bowel resection (other than appendectomy), gastric bypass, or other bariatric weight loss procedure
  11. GI diseases, conditions or meds known to influence GI absorption including active peptic ulcer disease or inflammatory bowel disease (such as ulcerative colitis, Crohn's disease), Celiac disease, Cystic Fibrosis, malabsorption disorders, gallbladder disease, acute or chronic pancreatitis or Pancreatic insufficiency
  12. Chronic kidney disease or history of kidney stones
  13. History of diagnosed eating disorder anorexia, bulimia or binge-eating
  14. Active treatment for cancer (except non-melanoma skin cancer) of any type in ≤ 3 year.
  15. Thyroid disease or other significant endocrine disorder
  16. Uncontrolled hypercholesterolemia.
  17. History of acute or chronic pancreatitis or gall bladder disease.
  18. Metabolic disorders or conditions that interfere with nutrient absorption (such as Phenylketonuria, Maple Syrup Urine Disease, glucose-galactose malabsorption, ornithine transcarbamylase deficiency or hypophosphatemic rickets.)
  19. Dose adjustment to statin or antihypertensive medication within the past 3 months
  20. Screening lab results outside the normal parameters that may interfere with study outcomes at the discretion of study MD
  21. Inadequate venous access or history of a bilateral mastectomy with nodal dissection
  22. Recent history of inflammatory diseases (for example: rheumatoid arthritis, lupus)
  23. Active WL, or weight change > 4 kg in past 6 months.
  24. Consuming a restrictive diet (e.g. gluten-free, vegan, Paleolithic diet).
  25. Self-reported allergy to any ingredient in the provided intervention foods.
  26. Self-reported severe allergy to adhesives.
  27. Unwilling to use a mobile phone or computer with videoconference software to participate in intervention group meetings. Unwilling to eat on camera.
  28. Reports of consumption of > 2 alcoholic drinks per day on average or >14/week (168oz beer/56oz wine/14oz hard liquor.)
  29. Reports of consumption of > 2 cups of green or black tea per day on average.
  30. Reports of use of recreational and/or illegal drugs.
  31. Regular smoking or vaping tobacco or marijuana including the use of edibles within the last 6 months (greater than once a week)
  32. Non-English speakers.
  33. No social security number (required for stipend payment).

Sites / Locations

  • Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Placebo Comparator

Active Comparator

No Intervention

Arm Label

+MCNS+WL

-MCNS+WL

+MCNS-WL

-MCNS-WL

Arm Description

This group receives the multicomponent nutrition supplement and the behavioral weight loss intervention.

This group receives the placebo nutrition supplement and the behavioral weight loss intervention.

This group receives the multicomponent nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes).

This group receives the placebo nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes)

Outcomes

Primary Outcome Measures

Cognitive function
Change in age-sensitive cognitive composite z-score from baseline, based on well-established standardized scores on 5 neuropsychological tests (Controlled Oral; Word Association Test, Digit Symbol Substitution Test; Stroop Interference Test; Trails Making Tests A and B)

Secondary Outcome Measures

Microvascular cerebral blood flow in fasting state
Change in microvascular cerebral blood flow from baseline, measured with diffuse correlation spectroscopy / near infrared spectroscopy during fasting state
Microvascular cerebral blood flow in fed state
Change in microvascular cerebral blood flow from baseline, measured with diffuse correlation spectroscopy / near infrared spectroscopy during fed state
Macrovascular cerebral blood flow velocity in fasting state
Change in macrovascular cerebral blood flow velocity measured with transcranial Doppler ultrasound measured during fasting state
Macrovascular cerebral blood flow velocity in fed state
Change in macrovascular cerebral blood flow velocity measured with transcranial Doppler ultrasound measured during fed state

Full Information

First Posted
August 9, 2022
Last Updated
September 13, 2022
Sponsor
Tufts University
Collaborators
Massachusetts General Hospital, University of Florida, University of New Hampshire
search

1. Study Identification

Unique Protocol Identification Number
NCT05542199
Brief Title
Nutrition for Brain and Body Health (BB-Health) Feasibility Trial
Acronym
BB-Health
Official Title
Food Supplement Approach for Prevention of Age-associated Cognitive Decline in Older Adults With Obesity: the Nutrition for Brain and Body Health (BB-Health) Feasibility Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 13, 2022 (Actual)
Primary Completion Date
October 1, 2023 (Anticipated)
Study Completion Date
November 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tufts University
Collaborators
Massachusetts General Hospital, University of Florida, University of New Hampshire

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of the trial is to determine the feasibility of implementing a specific nutrition regimen used alone or in combination with a behavioral weight loss (WL) intervention on cognition and cerebral blood flow in older adults at risk of cognitive decline.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cognition, Obesity

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Model Description
A 2x2 factorial design in which participants are assigned to the multicomponent nutrition supplement or a placebo, and to participation in a behavioral weight loss intervention or to a wait-list control
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Masking occurs after randomization. Participants and investigators and outcome assessors are masked to the assignment to the nutritional supplement vs placebo. Investigators responsible for the weight loss intervention, and outcome assessors, are masked to the assignment to the behavioral weight loss intervention versus the wait-list control.
Allocation
Randomized
Enrollment
48 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
+MCNS+WL
Arm Type
Active Comparator
Arm Description
This group receives the multicomponent nutrition supplement and the behavioral weight loss intervention.
Arm Title
-MCNS+WL
Arm Type
Placebo Comparator
Arm Description
This group receives the placebo nutrition supplement and the behavioral weight loss intervention.
Arm Title
+MCNS-WL
Arm Type
Active Comparator
Arm Description
This group receives the multicomponent nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes).
Arm Title
-MCNS-WL
Arm Type
No Intervention
Arm Description
This group receives the placebo nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes)
Intervention Type
Other
Intervention Name(s)
Multicomponent nutrition supplement (MCNS)
Intervention Description
Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
Intervention Type
Behavioral
Intervention Name(s)
Behavioral weight loss program
Intervention Description
Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
Primary Outcome Measure Information:
Title
Cognitive function
Description
Change in age-sensitive cognitive composite z-score from baseline, based on well-established standardized scores on 5 neuropsychological tests (Controlled Oral; Word Association Test, Digit Symbol Substitution Test; Stroop Interference Test; Trails Making Tests A and B)
Time Frame
Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Secondary Outcome Measure Information:
Title
Microvascular cerebral blood flow in fasting state
Description
Change in microvascular cerebral blood flow from baseline, measured with diffuse correlation spectroscopy / near infrared spectroscopy during fasting state
Time Frame
Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Title
Microvascular cerebral blood flow in fed state
Description
Change in microvascular cerebral blood flow from baseline, measured with diffuse correlation spectroscopy / near infrared spectroscopy during fed state
Time Frame
Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Title
Macrovascular cerebral blood flow velocity in fasting state
Description
Change in macrovascular cerebral blood flow velocity measured with transcranial Doppler ultrasound measured during fasting state
Time Frame
Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Title
Macrovascular cerebral blood flow velocity in fed state
Description
Change in macrovascular cerebral blood flow velocity measured with transcranial Doppler ultrasound measured during fed state
Time Frame
Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization
Other Pre-specified Outcome Measures:
Title
Weight loss
Description
Change in body weight from baseline
Time Frame
Measure at baseline (pre-randomization), and 3, 6 and 12 months after randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Major inclusion criteria: Adult women and men aged 55-85 years. BMI of 27.0-39.9 kg/m2 at screening (higher BMIs not included at this time to facilitate program adherence); Scores of 34 or greater on the Modified Telephone Interview for Cognitive Status (TICS-M) at screening (85). The purpose of this screen is to ensure that participants can give consent and adhere to the study requirements, including the outcomes testing. Willing to be randomized and participate in all study components, including consuming the foods and supplements, participating in the WL intervention or control meetings, being available for outcome assessments, using the provided home Wi-Fi scale and activity monitor daily, and completing questionnaires, as well as providing the login information for scales and activity monitor so investigators can download the data. Satisfactory screening review of health history questionnaire by nursing staff for relevant factors including no evidence of exclusions listed below. This will include verbal confirmation of completing a course of vaccination against COVID-19 (two doses plus one booster prior to screening visit). The reason for this study component is that live group meetings are planned with other participants, and this will reduce participant risk. Has access to computer or smartphone with Wi-Fi and possesses a freezer at home with space for supplement storage. Rates representative food with characteristics of the MCNS and control foods at least 4 on a 5-point scale of liking at screening, and reports that they are willing to consume the food daily. Average energy intake in 3 24-h dietary recalls is within physiological (i.e., plausible) range. Major exclusion criteria: >25% percentile in most recent data for US adult population intake for reported DHA/EPA in screening questionnaire for rich food sources, which is equivalent to 2 or more servings of fatty fish/month (86, 87). Regularly taking a multivitamin, cacao/cocoa supplement, choline supplement, DHA/EPA supplement, or any supplement advertised for brain health or cognitive function (>1/week). Washout period of 2 months accepted. Does not like, or alternatively reports eating >1 serving per week of >60% chocolate or cocoa. Severe cardiovascular disease including stroke, heart failure, coronary bypass and valve replacement, coronary bypass or any surgical procedures or signs and symptoms of current severe cardiovascular disease. History of neurological brain disease, including stroke, seizure disorders, traumatic brain injury (moderate to severe); including prior diagnosis of a neurodegenerative disease including AD and Parkinson's disease, frontotemporal dementia. Moderate traumatic brain injury is defined by an injury with loss of consciousness. Major psychiatric disorder history (schizophrenia, bipolar affective disorder, intractable depression). Inadequately controlled hypertension at the discretion of study MD or RN Diabetes Type 1 & Type 2 or use of any pharmacological treatment for diabetes or HbA1c >6.5 at screening. Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol. This includes the lost of smell or taste. History of stomach or bowel resection (other than appendectomy), gastric bypass, or other bariatric weight loss procedure GI diseases, conditions or meds known to influence GI absorption including active peptic ulcer disease or inflammatory bowel disease (such as ulcerative colitis, Crohn's disease), Celiac disease, Cystic Fibrosis, malabsorption disorders, gallbladder disease, acute or chronic pancreatitis or Pancreatic insufficiency Chronic kidney disease or history of kidney stones History of diagnosed eating disorder anorexia, bulimia or binge-eating Active treatment for cancer (except non-melanoma skin cancer) of any type in ≤ 3 year. Thyroid disease or other significant endocrine disorder Uncontrolled hypercholesterolemia. History of acute or chronic pancreatitis or gall bladder disease. Metabolic disorders or conditions that interfere with nutrient absorption (such as Phenylketonuria, Maple Syrup Urine Disease, glucose-galactose malabsorption, ornithine transcarbamylase deficiency or hypophosphatemic rickets.) Dose adjustment to statin or antihypertensive medication within the past 3 months Screening lab results outside the normal parameters that may interfere with study outcomes at the discretion of study MD Inadequate venous access or history of a bilateral mastectomy with nodal dissection Recent history of inflammatory diseases (for example: rheumatoid arthritis, lupus) Active WL, or weight change > 4 kg in past 6 months. Consuming a restrictive diet (e.g. gluten-free, vegan, Paleolithic diet). Self-reported allergy to any ingredient in the provided intervention foods. Self-reported severe allergy to adhesives. Unwilling to use a mobile phone or computer with videoconference software to participate in intervention group meetings. Unwilling to eat on camera. Reports of consumption of > 2 alcoholic drinks per day on average or >14/week (168oz beer/56oz wine/14oz hard liquor.) Reports of consumption of > 2 cups of green or black tea per day on average. Reports of use of recreational and/or illegal drugs. Regular smoking or vaping tobacco or marijuana including the use of edibles within the last 6 months (greater than once a week) Non-English speakers. No social security number (required for stipend payment).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Susan B. Roberts, Ph.D.
Phone
617-556-3237
Email
susan.roberts@tufts.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Rachel E. Silver, Ph.D., M.P.H.
Phone
617-556-3237
Email
rachel.silver@tufts.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan B. Roberts, Ph.D.
Organizational Affiliation
Jean Mayer USDA Human Nutrition Research Center on Aging
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02111
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rachel E. Silver, Ph.D., M.P.H.
Phone
617-556-3237
Email
rachel.silver@tufts.edu
First Name & Middle Initial & Last Name & Degree
Susan B. Roberts, Ph.D.
Phone
617-556-3237
Email
susan.roberts@tufts.edu
First Name & Middle Initial & Last Name & Degree
Susan B. Roberts, Ph.D.

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified data will be shared consistent with NIH policies.
IPD Sharing Time Frame
Within 12 months of publication of the primary paper.

Learn more about this trial

Nutrition for Brain and Body Health (BB-Health) Feasibility Trial

We'll reach out to this number within 24 hrs